Effect of Exenatide on Cortisol Secretion

NCT03160261 on ClinicalTrials.gov · last registry update 2018-05-03

A small phase 4 — 10 participants, against a typical 75. The sponsor logged completion for 28 December 2017. Primary outcome, as filed: Cortisol peak.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Tartu
Sponsor type: Other
Enrollment: 10
Started: 2017-09-07
Primary completion: 2017-12-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Cortisol peak

Conditions studied

Healthy

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.